Individualized concurrent chemotherapy by pretreatment plasma Epstein‐Barr viral DNA in II‐III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort-Reference-Cited by-同舟云学术

Individualized concurrent chemotherapy by pretreatment plasma Epstein‐Barr viral DNA in II‐III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort

Published:2019-06-18 Issue:9 Volume:8 Page:4214-4225
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Sun Xue‐Song¹²³⁴,Chen Wen‐Hui⁵,Liu Sai‐Lan¹²³⁴,Liang Yu‐Jing¹²³⁴,Chen Qiu‐Yan¹²³⁴,Guo Shan‐Shan¹²³⁴,Wen Yue‐Feng¹²³⁴,Liu Li‐Ting¹²³⁴,Xie Hao‐Jun¹²³⁴,Tang Qing‐Nan¹²³⁴,Li Xiao‐Yun¹²³⁴,Yan Jin‐Jie¹²³⁴,Mai Hai‐Qiang¹²³⁴,Tang Lin‐Quan¹²³⁴^ORCID

Affiliation:

1. Sun Yat‐sen University Cancer Centre Guangzhou P. R. China

2. State Key Laboratory of Oncology in South China Guangzhou P. R. China

3. Collaborative Innovation Centre for Cancer Medicine Guangzhou P. R. China

4. Department of Nasopharyngeal Carcinoma Sun Yat‐sen University Cancer Centre Guangzhou P. R. China

5. Department of Oncology The First Affiliated Hospital, Jinan University Guangzhou China

Funder

National Natural Science Foundation of China

Natural Science Foundation of Guangdong Province

Sun Yat-sen University

Publisher

Wiley